Encompass Health (EHC)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$121.79-0.65%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · EHC
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-09-06. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $122 EHC trades at 21× p/e, below its 23× p/e peer median, but our blended $96 fair value sits below the price. We hold it with low confidence: our number sits well below the analyst range and quality doesn't explain valuation multiples in this sub-industry, so the peer comparison is a weak guide. Analysts target $144–$155. Note: our $96 fair value sits below the entire analyst range ($144–$155). Even valued only for durable growth at sustainable margins, it's worth about $133 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $151.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $317.73 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $296.74 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $15.79 | — | — | TTM | high |
| graham number | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$144.00 – $155.00 (median $151.00) · 4 analysts · as of 2026-08-07
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 289% over what the business is worth with no growth; closing that gap needs roughly 29.8 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $1.30/sh owner earnings.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $66.87 |
| — |
| — |
| TTM |
| high |
| Peer EV/EBITDA | 12M | $26.69 | 6.2 | 8.36 | TTM | high |
| Peer P/FCF | 12M | $69.80 | 16.9 | 4.13 | TTM | high |
| Peer P/E | 12M | $135.48 | 23.2 | 5.84 | TTM | high |
| Peer P/S | 12M | $66.55 | 1.1 | 62.06 | TTM | high |
| PEG | 12M | $86.23 | 14.8 | 5.84 | TTM | high |
| residual income | 12M | $47.61 | — | — | TTM | high |
| Own P/E history | 12M | $113.13 | 19.4 | 5.84 | TTM | high |
| triangulated | 12M | $150.65 | 23.2 | 6.49 | Triangulated | high |
| Peer P/FCF | 3Y | $106.16 | 16.9 | 6.29 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $164.16 | 23.2 | 7.08 | Analyst | medium |
| Peer P/S | 3Y | $79.46 | 1.1 | 74.11 | guidance | medium |
| PEG | 3Y | $104.48 | 14.8 | 7.08 | Analyst | medium |
| Own P/E history | 3Y | $137.07 | 19.4 | 7.08 | Analyst | medium |
| Peer P/FCF | 5Y | $140.39 | 16.9 | 8.31 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $175.39 | 23.2 | 7.56 | Analyst | high |
| Peer P/S | 5Y | $84.90 | 1.1 | 79.18 | guidance | high |
| PEG | 5Y | $111.64 | 14.8 | 7.56 | Analyst | high |
| Own P/E history | 5Y | $146.46 | 19.4 | 7.56 | Analyst | high |